Protein abundance of KCNH1 was comparable to targets under development in neuroblastoma including NCAM1, L1CAM and CD276, and higher than other known immunotherapeutic targets such as ALK and GPC2 (Fig. 6B). This evidence concerns the gene CD276 and neuroblastoma.